Novo Nordisk is ”very enagaged” in India, the CFO says, but the weight-loss drug will not be launched there until 2025. Photo: Tom Little BY CHRISTIAN BUNDGAARD28 May 2024at 09:50 People with obesity in India will have to wait to get access to Novo Nordisk’s big seller Wegovy, according to the local Indian media Business...
GLP-1-targeting drugs like Wegovy and Zepbound have helped patients with obesity lose about a fifth of their body weight. But roughly 40% of that weight could be lean mass, which is a concern for some experts — and a potential opportunity for other drugmakers. As STAT’s Allison DeAngelis and Elaine Chen report, the idea of...
By Elaine Chen This image provided by Novo Nordisk in January 2023, shows packaging for the company’s Wegovy drug.NOVO NORDISK VIA AP PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss. The company in August had...
